IN BRIEF: Syncona investee Achilles Therapeutics files for US IPO

Syncona Ltd - investor in life science companies - Portfolio firm Achilles Therapeutics PLC files ...

Alliance News 2 March, 2021 | 1:45PM
Email Form

Syncona Ltd - investor in life science companies - Portfolio firm Achilles Therapeutics PLC files with US Securities & Exchange Commission for a proposed initial public offering of American Depositary Shares. JP Morgan, BofA Securities and Piper Sandler are expected to be book-running managers for the IPO, with Chardan, Oppenheimer & Co and Kempen & Co as co-managers. Syncona says the number ADSs to be sold and the pricing have not yet been set. Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumours.

Current stock price: 254.38 pence

Year-to-date change: down 2.5%

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Syncona Ord 245.50 GBX -1.60 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies       Modern Slavery Statement